Nevertheless, our IRS signature indicated strong prognostic ability and even outperformed tumor stages (GSE31210: stage IA-II; GSE50081: stage IA-IIA) in the early-stage NSCLC patients. This evidence concerns the gene IARS1 and neoplasm.